Windtree Therapeutics announced positive Phase 2b results for istaroxime in treating cardiogenic shock. The study showed improvement in blood pressure and cardiac function over 96 hours, with promising safety. Detailed results will be presented at the Heart Failure Society of America Meeting in September.